Patterns of Therapy Switching, Augmentation, and Discontinuation After Initiation of Treatment With Select Medications in Patients With Osteoarthritis

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 1914-1931

  Gore, Mugdha ^a   Sadosky, Alesia ^b   Leslie, Douglas ^c   Tai, Kei Sing ^a   Seleznick, Mitchel ^d  

^a Avalon Health Solutions Inc   (United States)

^b PFIZER INC   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Augmentation; Discontinuation; Medications; Osteoarthritis; Switching

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; DIHYDROCODEINE; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMATE SODIUM; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXAPROZIN; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; ROFECOXIB; SULINDAC; TOLMETIN; TRAMADOL; UNINDEXED DRUG; VALDECOXIB;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; JOINT PROSTHESIS; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANALGESICS; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRALGIA; ARTHROPLASTY, REPLACEMENT; CHRONIC PAIN; CYCLOOXYGENASE 2 INHIBITORS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; OSTEOARTHRITIS; PAIN MEASUREMENT; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 83455220110     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.019     Document Type: Article

References (48)

1. Lawrence R.C., Felson D.T., Helmick C.G., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
2. Brandt K.D., Kovalov-St.John K. Osteoarthritis. Harrison's Principles of Internal Medicine 1991, 1475-1479. McGraw-Hill, New York, NY. 12th ed. J.D. Wilson, E. Braunwald, K.J. Isselbacher (Eds.).
3. Sharma L. Epidemiology of osteoarthritis. Osteoarthritis: Diagnosis and Medical/Surgical Management 2001, 3-17. WB Saunders, Philadelphia, Pa. 3rd ed. R.W. Moskowitz, O.S. Howell, R.D. Altman (Eds.).
4. Rakel R.E. Rheumatology and musculoskeletal problems. Textbook of Family Medicine 2007, 915-954. Saunders Elsevier, Philadelphia, Pa. 7th ed.
5. Porter M.E. What is value in health care?. N Engl J Med 2010, 363:2477-2481.
6. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
7. Leardini G., Salaffi F., Caporali R., et al. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol 2004, 22:699-706.
8. Rabenda V., Manette C., Lemmens R., et al. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 2006, 33:1152-1158.
9. Gupta S., Hawker G.A., Laporte A., et al. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatol (Oxford) 2005, 44:1531-1537.
10. Gabriel S.E., Crowson C.S., Campion M.E., O'Fallon W.M. Direct medical costs unique to people with arthritis. J Rheumatol 1997, 24:719-725.
11. Dunn J.D., Pill M.W. A claims-based view of health care charges and utilization for commercially insured patients with osteoarthritis. Manag Care 2009, 18:44-50.
12. Yelin E., Murphy L., Cisternas M.G., et al. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum 2007, 56:1397-1407.
13. Kotlarz H., Gunnarsson C.L., Fang H., Rizzo J.A. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009, 60:3546-3553.
14. Kotlarz H., Gunnarsson C.L., Fang H., Rizzo J.A. Osteoarthritis and absenteeism costs: evidence from US National Survey Data. J Occup Environ Med 2010, 52:263-268.
15. Mapel D.W., Shainline M., Paez K., Gunter M. Hospital, pharmacy, and outpatient costs for osteoarthritis and chronic back pain. J Rheumatol 2004, 31:573-583.
16. White A.G., Birnbaum H.G., Janagap C., et al. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med 2008, 50:998-1005.
17. White L.A., Birnbaum H.G., Kaltenboeck A., et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008, 50:13-24.
18. Burton W.N., Chen C., Schultz A.B., et al. Worker productivity loss associated with arthritis. Dis Manag 2006, 9:131-143.
19. Abdel-Nasser A.M., Abd El-Azim S., Taal E., et al. Depression and depressive symptoms in rheumatoid arthritis patients: an analysis of their occurrence and determinants. Br J Rheumatol 1998, 37:391-397.
20. Keefe F.J., Bonk V. Psychosocial assessment of pain in patients with rheumatic diseases. Rheum Dis Clin North Am 1999, 25:81-103.
21. Jakobsson U., Hallberg I.R. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs 2002, 11:430-443.
22. Cook C., Pietrobon R., Hegedus E. Osteoarthritis and the impact on quality of life health indicators. Rheumatol Int 2007, 27:315-321.
23. Dominick K.L., Ahern F.M., Gold C.H., Heller D.A. Health-related quality of life and health service use among older adults with osteoarthritis. Arthritis Rheum 2004, 51:326-331.
24. Altman R.D., Hochberg M.C., Moskowitz R.W., Schnitzer T.J. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000, 43:1905-1915.
25. Zhang W., Moskowitz R.W., Nuki G., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000.
26. Zhang W., Moskowitz R.W., Nuki G., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
27. Jordan K.M., Arden N.K., Doherty M., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
28. Zhang W., Nuki G., Moskowitz R.W., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
29. Pincus T., Swearingen C., Cummins P., Callahan L.F. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000, 27:1020-1027.
30. Pincus T., Koch G., Lei H., et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931-939.
31. Pincus T., Wang X., Chung C., et al. Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: face validity of self-report questionnaire ratings. J Rheumatol 2005, 32:533-539.
32. Stockl K., Cyprien L., Chang E.Y. Gastrointestinal bleeding rates among managed care patients newly started on cox-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm 2005, 11:550-558.
33. Joshi G.P., Gertler R., Fricker R. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. Anesth Analg 2007, 105:1793-1804.
34. Straube S., Tramèr M.R., Moore R.A., et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009, 9:41.
35. Avouac J., Gossec L., Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007, 15:957-965.
36. Fishbain D.A., Cole B., Lewis J.E., et al. Do opioids induce hyperalgesia in humans?. An evidence-based structured review. Pain Med 2009, 10:829-839.
37. Jamison R.N., Anderson K.O., Peeters-Asdourian C., Ferrante F.M. Survey of opioid use in chronic nonmalignant pain patients. Reg Anesth 1994, 19:225-230.
38. Donner B., Raber M., Zenz M., et al. Experiences with the prescription of opioids: a patient questionnaire. J Pain Symptom Manag 1998, 15:231-234.
39. Weinstein S.M., Laux L.F., Thornby J.I., et al. Physicians' attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J 2000, 93:479-487.
40. Turk D.C., Brody M.C., Okifuji E.A. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 1994, 59:201-208.
41. Bhamb B., Brown D., Hariharan J., et al. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006, 22:1859-1865.
42. McCracken L.M., Hoskins J., Eccleston C. Concerns about medication and medication use in chronic pain. J Pain 2006, 7:726-734.
43. Solomon D.H., Rassen J.A., Glynn R.J., et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010, 170:1968-1978.
44. Scholes D., Stergachis A., Penna P.M., et al. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995, 22:708-712.
45. Zhao S.Z., Wentworth C., Burke T.A., Makuch R.W. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf 2004, 13:277-287.
46. Theiler R., Bischoff H.A., Good M., Uebelhart D. Rofecoxib improves quality of life in patients with hip or knee osteoarthritis. Swiss Med Wkly 2002, 132:566-573.
47. van Dijk G.M., Veenhof C., Schellevis F., et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008, 9:95.
48. Chan K.W., Ngai H.Y., Ip K.K., et al. Co-morbidities of patients with knee osteoarthritis. Hong Kong Med J 2009, 15:168-172.